Literature DB >> 18821214

HLA-class II alleles in Egyptian patients with hepatocellular carcinoma.

Farha A El-Chennawi1, Fatma A Auf, Shereen S Metwally, Youssef M Mosaad, Mohamed A El-Wahab, Ziyad E Tawhid.   

Abstract

UNLABELLED: Hepatocellular carcinoma (HCC) is linked to environmental, dietary, and life style factors. Its incidence and distribution vary widely among ethnic groups, sex, and geographic regions. HBV and HCV Infection, liver cirrhosis, male gender, and old age are important risk factors of HCC. Variability in outcome following exposure, and the clustering of HCC within families raise the possibility that genetic factors are also involved in susceptibility to HCC. The Major Histocompatibility Complex (MHC) plays a key role in anti-virus and tumor defense. HLA polymorphism is implicated in conferring genetic susceptibility to a large number of immune-mediated diseases, including some cancers. The association between HLA class II antigen and HCC in different ethnic populations that has been reported is controversial. Therefore, the aim of this work was to study the association between HLA class II-DRB1 and DQB1 polymorphism and HCC in Egyptian patients and to investigate their role as risk factors for the development of HCC.
METHODS: HLA-class II (DRB1 and DQB1) typing was done by SSP for 100 subjects; 50 patients suffering from HCC (45 males and 5 females) with age range 40-64 years (51.16 years (y) +/- 6.16); and 50 normal healthy control subjects.
RESULTS: 1. A significantly increased frequency of DRB1*04, and DQB1 *02 in HCC patients versus control group (p = 0.016, and 0.032, respectively) was found; 2. A significantly decreased frequency of DQB1*06 (p = 0.032) was found; 3. A significantly increased frequency of DRB1*07 (odds ratio (OR) = 4.929) was found; and 4. A significantly decreased frequency of DRB1*15 (OR = 0.316) was seen. In conclusion, while some alleles are significantly associated with HCC (DRB1*04, DQB1*02) and others are not associated (DQB1*06); therefore, it can be concluded that the DRB1*04 and DQB1*02 alleles might be risk factors for the occurrence of HCC (OR = 4.373 and 3.807, respectively), and DQB1*06 may be a protective allele (OR = 0.259).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18821214     DOI: 10.1080/08820130802111605

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  10 in total

1.  Specific HLA-DQB1 alleles associated with risk for development of hepatocellular carcinoma: a meta-analysis.

Authors:  Yong-Ning Xin; Zhong-Hua Lin; Xiang-Jun Jiang; Shu-Hui Zhan; Quan-Jiang Dong; Qing Wang; Shi-Ying Xuan
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

2.  Human leukocyte antigen-DRB1*1501 and DQB1*0602 alleles are cervical cancer protective factors among Uighur and Han people in Xinjiang, China.

Authors:  Jian Ming Hu; Qi Sun; Ling Li; Chun Xia Liu; Yun Zhao Chen; Hong Zou; Li Juan Pang; Jin Zhao; Lan Yang; Yu Wen Cao; Xiao Bin Cui; Yan Qi; Wei Hua Liang; Wen Jie Zhang; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Relationship between HLA-DRB1 allele polymorphisms and familial aggregations of hepatocellular carcinoma.

Authors:  S Ma; J Wu; J Wu; Y Wei; L Zhang; Q Ning; D Hu
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

4.  Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: a meta-analysis.

Authors:  Zhong-Hua Lin; Yong-Ning Xin; Quan-Jiang Dong; Qing Wang; Xiang-Jun Jiang; Shu-Hui Zhan; Ying Sun; Shi-Ying Xuan
Journal:  BMC Gastroenterol       Date:  2010-12-21       Impact factor: 3.067

5.  A comprehensive analysis of the dynamic biological networks in HCV induced hepatocarcinogenesis.

Authors:  Bing He; Hao Zhang; Tieliu Shi
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

6.  GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers.

Authors:  Shengping Li; Ji Qian; Yuan Yang; Wanting Zhao; Juncheng Dai; Jin-Xin Bei; Jia Nee Foo; Paul J McLaren; Zhiqiang Li; Jingmin Yang; Feng Shen; Li Liu; Jiamei Yang; Shuhong Li; Shandong Pan; Yi Wang; Wenjin Li; Xiangjun Zhai; Boping Zhou; Lehua Shi; Xinchun Chen; Minjie Chu; Yiqun Yan; Jun Wang; Shuqun Cheng; Jiawei Shen; Weihua Jia; Jibin Liu; Jiahe Yang; Zujia Wen; Aijun Li; Ying Zhang; Guoliang Zhang; Xianrong Luo; Hongbo Qin; Minshan Chen; Hua Wang; Li Jin; Dongxin Lin; Hongbing Shen; Lin He; Paul I W de Bakker; Hongyang Wang; Yi-Xin Zeng; Mengchao Wu; Zhibin Hu; Yongyong Shi; Jianjun Liu; Weiping Zhou
Journal:  PLoS Genet       Date:  2012-07-12       Impact factor: 5.917

7.  Genetic susceptibility of eight nonsynonymous polymorphisms in HLA-DRB1 gene to hepatocellular carcinoma in Han Chinese.

Authors:  Yanhui Shi; Weiyu Zhai; Bin Wang; Dongmei Zhao; He Jin; Yuefei Wang; Jidong Zhang; Hongjun An; Zhongze Fu; Kun Zhao; Changzhu Lu
Journal:  Oncotarget       Date:  2016-12-06

8.  Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4.

Authors:  Olfat Shaker; Heba Bassiony; Maissa El Raziky; Samer S El-Kamary; Gamal Esmat; Akmal M El-Ghor; Mona M Mohamed
Journal:  Mediators Inflamm       Date:  2013-03-14       Impact factor: 4.711

9.  Genome-wide association pathway analysis to identify candidate single nucleotide polymorphisms and molecular pathways associated with TP53 expression status in HBV-related hepatocellular carcinoma.

Authors:  Xiwen Liao; Long Yu; Xiaoguang Liu; Chuangye Han; Tingdong Yu; Wei Qin; Chengkun Yang; Guangzhi Zhu; Hao Su; Tao Peng
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989

10.  HLA-DQA1 & DQB1 variants associated with hepatitis B virus-related chronic hepatitis, cirrhosis & hepatocellular carcinoma.

Authors:  Vijay Kumar Karra; Soumya Jyoti Chowdhury; Rajesh Ruttala; Phani Kumar Gumma; Sunil Kumar Polipalli; Anita Chakravarti; Premashis Kar
Journal:  Indian J Med Res       Date:  2018-06       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.